China began offering free human papillomavirus (HPV) vaccines to girls turning 13 years old on November 10, 2025, a move lauded by the World Health Organization as a “historic milestone” in the country’s efforts to prevent cervical cancer. The nationwide rollout, yet, faces challenges beyond simply removing financial barriers to access, with public health officials now focused on logistical hurdles and growing vaccine hesitancy among parents.
While the financial cost of the vaccine has been eliminated for eligible girls – those born on or after November 10, 2011 – achieving widespread coverage requires overcoming obstacles related to physical access to vaccination sites and addressing increasing parental skepticism. These challenges are proving to be as significant as the initial cost concerns, according to experts.
During a recent symposium hosted by the Duke Kunshan University Vaccine Delivery Research Innovation Lab, Chinese public health officials acknowledged a rise in vaccine hesitancy in recent years. To reach the World Health Organization’s goal of 90% vaccine coverage among girls by age 15, experts emphasized the need for improved coordination between health and education departments.
Globally, schools have proven to be the most effective locations for administering HPV vaccines. A study of 92 countries, cited by Liu Qin from Chongqing Medical University, found that nearly two-thirds utilize in-school vaccination programs, resulting in immunization rate increases of up to 5.5% in France, particularly within underserved communities.
However, China’s current vaccination programs primarily rely on community health service centers and maternal and child health hospitals, rather than schools. Direct vaccine delivery within school grounds is uncommon, creating logistical difficulties in reaching all eligible students. This contrasts with strategies employed in countries like Australia and Singapore, where school-based programs are standard practice.
Some provinces, like Jiangxi, have demonstrated success through interdepartmental collaboration, achieving an 80% vaccination rate among 1.5 million administered doses since 2023. Despite this progress, weekend clinic visits – requiring parental accompaniment – remain the primary method of delivery, highlighting the ongoing logistical challenges. The National Health Commission has responded by encouraging extended clinic hours, but experts maintain that in-school vaccination would maximize coverage.
Adding to the logistical complexities, rising levels of parental vaccine hesitancy present a significant barrier. As recipients are minors, guardian consent is mandatory, and officials have observed an increase in resistance since 2023. Studies indicate that nearly 70% of parents who decline the vaccine for their children express distrust in its efficacy or believe natural immunity is sufficient.
A pilot survey conducted by Duke Kunshan University revealed a decline in student participation in HPV vaccination programs, regardless of notification methods, suggesting growing parental refusal. This trend mirrors developments in other countries, including Australia, where coverage rates have decreased since 2024, partly attributed to post-pandemic vaccine fatigue.
In China, social media algorithms are exacerbating parental fears by amplifying misinformation regarding vaccine side effects, such as infertility or ovarian failure, despite the lack of scientific evidence supporting these claims. Medical specialists emphasize that adverse event rates for the HPV vaccine (30.38 per 100,000 doses between 2017 and 2020) are lower than the overall average for all vaccines administered in China, and that these events are not causally linked side effects.
To combat hesitancy, officials are advocating for “vaccine health education prescriptions,” where doctors proactively discuss and recommend the vaccine during routine checkups. Clear and accurate guidance from well-informed doctors is considered crucial for dispelling myths and rebuilding public trust in HPV vaccination programs.
